In terms of mechanism, isoorientin acts as a modulator that controls the SIRT6/NRF2/GPX4 signaling pathway (downregulation of the expression of SIRT6 protein, NRF2, and GPX4), thereby regulating ferroptosis and reversing drug resistance in lung cancer cells [126]. Here, GPX4 is linked to lung carcinoma.